Cardiovasc Diabetol:2型糖尿病患者体重减轻程度和体重变异性与死亡率和主要心血管事件的关系

2022-05-28 从医路漫漫 MedSci原创

严重肥胖的T2DM患者在接受减肥手术后体重显著减轻,已被证明可降低死亡率和心血管事件的风险。

背景:目前的指南大力提倡超重或肥胖的二型糖尿病患者(T2DM)进行体重管理,以降低糖尿病并发症的风险并改善预后。严重肥胖的T2DM患者在接受减肥手术后体重显著减轻,已被证明可降低死亡率和心血管事件的风险。研究还表明有意减肥可以缓解糖尿病并改善血压和血脂控制。此外,根据一项大型前瞻性临床试验的事后分析,在超重的T2DM参与者中,强化生活方式干预后体重减轻10%以上与较低的心血管事件发生率相关。糖尿病诊断后一年内体重适度减轻也与10年后心血管事件风险降低相关。然而,多项研究发现,体重减轻对T2DM患者的全因死亡率和主要心血管事件没有影响或不利影响。体重减轻是T2DM的常见症状,这可归因于高血糖症和高胰岛素血症诱导的蛋白质分解代谢和肌肉氧化损伤加重[13]。大量无意的体重减轻表明骨骼和肌肉组织的损失,并与死亡和心血管事件的风险增加相关。之前对2019年7月之前发表的研究进行的系统综述发现,体重增加与心血管疾病(CVD)和死亡率的风险增加有关,而体重减轻对死亡率和心血管结局的影响尚不清楚。

目的:我们进行了系统综述和荟萃分析,纳入了最近2年发表的其他相关研究。本研究的目的是综合现有证据,说明在没有行为干预的情况下,体重减轻对T2DM患者全因死亡率和主要心血管事件的影响。

方法:我们在PubMed、Embase和Cochrane图书馆数据库中搜索研究体重减轻或体重变异与死亡率和心血管结局之间关系的研究。根据基线体重下降百分比测量体重下降并将其分层为> 10%和5–10%的研究结果,或使用随机效应模型汇总计算体重可变性的研究结果。使用纽卡斯尔-渥太华量表评估研究质量。

结果:30项符合条件的研究纳入系统评价,其中13项纳入荟萃分析。在T2DM患者中,体重大幅下降(> 10%)与全因死亡率风险增加相关(合并风险比(HR) 2.27,95% CI 1.51–3.42),主要心血管事件复合风险增加(合并HR 1.71,95% CI 1.38–2.12)和心血管死亡率风险增加(合并HR 1.50,95% CI 1.27–1.76)。中度体重减轻与全因死亡率(合并风险比1.17,95%可信区间0.97-1.41)或心血管结局(合并风险比1.12,95%可信区间0.94-1.33)无显著关联。体重差异与全因死亡率的高风险相关(合并风险比为1.54,95%可信区间为1.52-1.56)。

图1 重度和中度体重减轻的全因死亡率风险比的森林图

图2大剂量和中等剂量减肥的主要心血管事件风险比的森林图

图3大剂量和中等剂量体重减轻的心血管死亡率风险比的森林图

图4体重变异性的全因死亡率风险比的森林图。ASV,平均连续可变性;CV,变异系数;标准偏差

结论:体重大幅下降和体重大幅波动是T2DM患者死亡和心血管事件风险增加的潜在标志。保持稳定的体重可能对这些患者有积极的影响。

原文出处:Huang S,  Shi K,  Ren Y,et al.Association of magnitude of weight loss and weight variability with mortality and major cardiovascular events among individuals with type 2 diabetes mellitus: a systematic review and meta-analysis.Cardiovasc Diabetol 2022 May 16;21(1)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2023-03-19 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2022-07-04 docwu2019
  5. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1640159, encodeId=5ba0164015992, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 24 00:36:49 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939362, encodeId=abd71939362ee, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Mar 19 23:36:49 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643799, encodeId=0fb11643e99d3, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jan 21 20:36:49 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761934, encodeId=852c1e61934ba, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jul 04 09:36:49 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343037, encodeId=23ef134303e37, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383788, encodeId=7ed81383e88d4, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407251, encodeId=5f96140e251d5, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475277, encodeId=4eaa14e5277a4, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552803, encodeId=4e1815528036a, content=<a href='/topic/show?id=5ec6232e1bd' target=_blank style='color:#2F92EE;'>#主要心血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23271, encryptionId=5ec6232e1bd, topicName=主要心血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058f14296236, createdName=jiyangfei, createdTime=Fri May 27 07:36:49 CST 2022, time=2022-05-27, status=1, ipAttribution=)]

相关资讯

SCRT:脐带来源间充质干细胞治疗中国成人2型糖尿病的有效性和安全性

间充质干细胞(MSCs)是一种成体干细胞,通过分泌多种细胞因子和免疫抑制分子而具有强大的抗炎和免疫调节能力。

FDA批准双靶向2型糖尿病药物Mounjaro,它能帮助非糖尿病患者减重22.5%!

礼来(Eli Lilly)最近报告了 SURMOUNT-1研究的结果,显示该药物帮助没有 2 型糖尿病的患者减轻了高达 22.5% 的体重。

JCEM:舒张压和ACR是2型糖尿病患者动脉硬化可改变的危险因素

在没有明显的心血管疾病和慢性肾功能不全的情况下,2型糖尿病患者心踝血管指数通常为病理状态。DBP和ACR是2型糖尿病患者血管僵硬可改变的危险因素,因此需要对其进行进一步评估。

DOM:固定比例的甘精胰岛素联合利司那肽(iGlarLixi)可以改善2型糖尿病患者ß-细胞功能

对于许多成人2型糖尿病患者来说,胰高血糖素样肽-1受体激动剂(GLP-1RA)是一种合适的初始注射疗法,这一点已得到广泛共识。

Stroke:索马鲁肽对2型糖尿病患者卒中亚型的影响

与安慰剂相比,索马鲁肽降低了高心血管风险的2型糖尿病患者首次卒中的发生率,主要是由于预防了小血管阻塞。与安慰剂相比,索马鲁肽治疗降低了卒中的风险,而与基线时是否发生过卒中无关。原始出处:

DOM:三联疗法口服药物控制不佳的2型糖尿病患者加用替格列汀的有效性和安全性

肠道中肠促胰岛素和肾脏中钠-葡萄糖协同转运蛋白(SGLT)的功能障碍也有助于T2D的发病和进展,并且是克服T2D的有希望的靶点。